Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 14 December 2017, 11:03 HKT/SGT

Source: Hitachi, Ltd.
Partners Connected Health and Hitachi Develop an Explainable Ai Technology to Help Doctors Predict Readmissions and Improve Patient Outcomes
Novel AI technology accurately predicts the risk of readmission within 30 days for patients with heart failure, an important quality indicator in measuring hospital performance, potentially saving an additional $7,000 per patient.

TOKYO, Dec 14, 2017 - (JCN Newswire) - Partners Connected Health and Hitachi, Ltd. (TSE: 6501) today announced the development of artificial intelligence (AI) technology by Hitachi, in collaboration with Partners Connected Health, which can predict with high accuracy, the risk of hospital readmissions within 30 days for patients with heart failure. The AI technology helps select appropriate patients to participate in a readmission prevention program following hospital discharge, and can explain the reason why patients were identified as being at high risk. The 30-day readmission rate is regarded as one of the important indicators in hospital management, and can carry significant penalties for hospitals via the US Centers for Medicare and Medicaid (CMS) as part of the Affordable Care Act.
Example use situation/case of this AI technology in predicting readmission risk

This technology is an example of explainable AI, a new term currently defined as enabling machines to explain their decisions and actions to human users, and enabling them to understand, appropriately trust and effectively manage AI tools, while maintaining a high level of prediction accuracy.

"Traditional machine learning can help us predict events, but as end-users, we can't tell why the machine is predicting something a certain way," said Kamal Jethwani, MD, MPH, Senior Director, Partners Connected Health Innovation. "With this innovation, doctors and nurses using the algorithm will be able to tell exactly why a certain patient is at high risk for hospital admission, and what they can do about it. We want to enable our providers to act on this information, which is a step beyond the state-of-the-art today, in terms of machine learning algorithms."

As part of the study, the Partners Connected Health Innovation team simulated the readmission prediction program among heart failure patients participating in the Partners Connected Cardiac Care Program (CCCP), a remote monitoring and education program designed to improve the management of heart failure patients at risk for hospitalization.

These results were compared to data from approximately 12,000 heart failure patients hospitalized and discharged from the Partners HealthCare hospital network in 2014 and 2015. The analysis showed the prediction algorithm achieved a high accuracy of approximately AUC 0.71, and can significantly reduce the number of patient readmissions. (AUC, area under the curve, is a measure of prediction model performance with an ideal value range from 0 to 1.) As a result, approximately an additional US $7,000 savings per patient per year among the cohort of CCCP patients can be expected.

Hitachi's new AI technology uses deep learning to construct this prediction model. With conventional deep learning models, it is difficult for users to understand why the AI predicted a particular outcome. This presents a challenge for its adoption in healthcare. To address this problem, Hitachi developed a technology for risk prediction with analyzing the results presented by deep learning and extracting the several dozens of actionable factors for each patient from the vast amount of data collected from heart failure patients. These are elements familiar to clinicians and can support medical decision-making in clinical practice. Through a standard statistical approach based on this risk prediction model, the extracted factors were used to calculate the risk of hospital readmission, and the relevance of the factors was calculated. Thus, this explainable AI technology can enhance prediction accuracy and the quality of medical decision-making.

Hitachi and the Partners Connected Health Innovation team will jointly conduct a prospective study, which evaluates the prediction program by clinicians, and study how to integrate this within clinical workflows. By using this new AI technology, Hitachi will provide solutions for the medical field, including solutions for insurance and pharmaceutical companies, emergency services, and other healthcare services where prediction-based on medical data can be utilized.

About Partners Connected Health

Partners Connected Health, at Partners HealthCare, is leveraging information technology - mobile phones, tablets, wearables, sensors and remote health monitoring tools - to deliver quality patient care outside of traditional medical settings. Partners Connected Health programs are also helping providers and patients better manage chronic conditions, maintain health and wellness and improve adherence, engagement and clinical outcomes. The Connected Health team creates and deploys mobile technologies in a number of patient populations and care settings, and is conducting innovative research studies to test the effectiveness of mobile health technologies in various clinical applications, including medication adherence, care coordination, chronic disease management, prevention and wellness. Partners HealthCare, an integrated health system founded by Brigham and Women's Hospital and Massachusetts General Hospital, includes two academic medical centers, community and specialty hospitals, a managed care organization, community health centers, a physician network, home health and long-term care services, and other health care entities. Partners is a principal teaching affiliate of Harvard Medical School.

About Hitachi, Ltd.

Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, delivers innovations that answer society's challenges with our talented team and proven experience in global markets. The company's consolidated revenues for fiscal 2014 (ended March 31, 2015) totaled 9,761 billion yen ($81.3 billion). Hitachi is focusing more than ever on the Social Innovation Business, which includes power & infrastructure systems, information & telecommunication systems, construction machinery, high functional materials & components, automotive systems, healthcare and others. For more information on Hitachi, please visit the company's website at

Hitachi Ltd
Corporate Communications
Tel: +81-3-3258-1111

Dec 14, 2017 11:03 HKT/SGT
Source: Hitachi, Ltd.

Hitachi, Ltd. (TSE: 6501)

Topic: Press release summary
Sectors: Enterprise IT
From the Asia Corporate News Network

Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Example use situation/case of this AI technology in predicting readmission risk
View Image

Hitachi, Ltd.
Jan 18, 2018 15:42 HKT/SGT
Hitachi to Introduce New Innovations for Realizing Utility 3.0 via the Lumada IoT Platform at DistribuTECH 2018
Jan 16, 2018 13:29 HKT/SGT
Hitachi to Continue Team Penske Partnership in 2018
Jan 10, 2018 09:32 HKT/SGT
Hitachi to Expand its Clinical Reporting and Analytics for Diagnostic Imaging with the Acquisition of VidiStar
Jan 10, 2018 09:00 HKT/SGT
Hitachi Automotive Systems and Clarion Announce the Development of "Park-by-Memory"
Jan 10, 2018 08:34 HKT/SGT
Hitachi to Feature Advanced Mobility Technologies and Recruit Engineers at the 2018 NAIAS
Dec 15, 2017 13:38 HKT/SGT
Hitachi to Install New Proton Beam Therapy System in Spain
Dec 15, 2017 09:59 HKT/SGT
UK ABWR Successfully Completes GDA Process
Dec 14, 2017 11:39 HKT/SGT
Hitachi Promotes ASEAN Business Strategy at Board of Directors Meeting in Singapore
Dec 11, 2017 13:22 HKT/SGT
Hitachi Invests in Preferred Networks
Dec 8, 2017 10:47 HKT/SGT
Hitachi and Mitsubishi Electric Agree to Integrate Particle Therapy System Business
More news >>
 News Alerts
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: